Vertex Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.Vertex Pharmaceuticals (VRTX) shares fell 1.06% to $480.25 on Monday, marking its fifth consecutive day of losses and closing 10.01% below its 52-week high. The decline occurred during a broad market downturn, with the S&P 500 down 0.79%. While competitors like AbbVie and Krystal Biotech also saw minor declines, Arcturus Therapeutics dropped significantly by 3.73%, highlighting Vertex's underperformance relative to some peers despite the general negative sentiment.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Vertex Pharmaceuticals Inc. (VRTX) slid 1.06% to $480.25 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.79% to 7,515.34 and Dow Jones Industrial Average falling 0.26% to 52,498.64.
This was the stock's fifth consecutive day of losses.
Vertex Pharmaceuticals Inc. closed 10.01% short of its 52-week high of $533.67, which the company achieved on July 7th.
The stock demonstrated a mixed performance when compared to some of its competitors Monday, as AbbVie Inc. (ABBV) fell 0.03% to $248.00, Krystal Biotech Inc. (KRYS) fell 0.65% to $363.44, and Arcturus Therapeutics Holdings Inc. (ARCT) fell 3.73% to $6.71.
Data source: Dow Jones Market Data, FactSet. Data compiled July 13, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-13-26 1637ET